Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
How did HALO's recent EPS compare to expectations?
The most recent EPS for Halozyme Therapeutics Inc is $-0.24, not beating expectations of $2.24.
How did Halozyme Therapeutics Inc HALO's revenue perform in the last quarter?
Halozyme Therapeutics Inc revenue for the last quarter is $-0.24
What is the revenue estimate for Halozyme Therapeutics Inc?
According to 8 of Wall street analyst, the revenue estimate of Halozyme Therapeutics Inc range from $396.63M to $334.36M
What's the earning quality score for Halozyme Therapeutics Inc?
Halozyme Therapeutics Inc has a earning quality score of A/78.17323. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Halozyme Therapeutics Inc report earnings?
Halozyme Therapeutics Inc next earnings report is expected in 2026-05-18
What are Halozyme Therapeutics Inc's expected earnings?
Halozyme Therapeutics Inc expected earnings is $446.73M, according to wall-street analysts.
Did Halozyme Therapeutics Inc beat earnings expectations?
Halozyme Therapeutics Inc recent earnings of $451.76M beat expectations.